Literature DB >> 23359183

Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary?

D S Chang1, G K Bartlett, I J Das, H R Cardenes.   

Abstract

BACKGROUND AND
PURPOSE: External beam radiation therapy with concurrent chemotherapy (CRT) is widely used for the treatment of unresectable pancreatic cancer. Noncoplanar (NCP) 3D conformal radiotherapy (3DCRT) and coplanar (CP) IMRT have been reported to lower the radiation dose to organs at risk (OARs). The purpose of this article is to examine the utility of noncoplanar beam angles in IMRT for the management of pancreatic cancer.
MATERIALS AND METHODS: Sixteen patients who were treated with CRT for unresectable adenocarcinoma of the pancreatic head or neck were re-planned using CP and NCP beams in 3DCRT and IMRT with the Varian Eclipse treatment planning system.
RESULTS: Compared to CP IMRT, NCP IMRT had similar target coverage with slightly increased maximum point dose, 5,799 versus 5,775 cGy (p = 0.008). NCP IMRT resulted in lower mean kidney dose, 787 versus 1,210 cGy (p < 0.0001) and higher mean liver dose, 1,208 versus 1,061 cGy (p < 0.0001). Also, NCP IMRT resulted in similar mean stomach dose, 1,257 versus 1,248 cGy (p = 0.86) but slightly higher mean small bowel dose, 981 versus 866 cGy (p < 0.0001).
CONCLUSIONS: The NCP IMRT was able to significantly decrease bilateral kidney dose, but did not improve other dose-volume criteria. The use of NCP beam angles is preferred only in patients with risk factors for treatment-related kidney dysfunction.

Entities:  

Mesh:

Year:  2013        PMID: 23359183     DOI: 10.1007/s12094-012-0998-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  Dosimetric comparison of manual and beam angle optimization of gantry angles in IMRT.

Authors:  Shiv P Srivastava; Indra J Das; Arvind Kumar; Peter A S Johnstone
Journal:  Med Dosim       Date:  2010-09-03       Impact factor: 1.482

2.  Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.

Authors:  William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Ann Surg Oncol       Date:  2011-03-10       Impact factor: 5.344

3.  Conkiss: conformal kidneys sparing 3D noncoplanar radiotherapy treatment for pancreatic cancer as an alternative to IMRT.

Authors:  Zsolt Sebestyén; Péter Kovács; Ákos Gulybán; Róbert Farkas; Szabolcs Bellyei; Gábor Liposits; András Szigeti; Olga Esik; Katalin Dérczy; László Mangel
Journal:  Med Dosim       Date:  2010-01-22       Impact factor: 1.482

4.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

Authors:  J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

5.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

6.  An improved approach to external beam radiation therapy for intra-abdominal cavity lesions for rural cancer centers.

Authors:  Darren M Gearheart; Peggy Walker; Brad S Collett; Raghuram S Modur
Journal:  Med Dosim       Date:  2007       Impact factor: 1.482

7.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

8.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.

Authors:  Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

9.  Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity.

Authors:  Jerome C Landry; Gary Y Yang; Joseph Y Ting; Charles A Staley; William Torres; Natia Esiashvili; Lawrence W Davis
Journal:  Med Dosim       Date:  2002       Impact factor: 1.482

10.  Three-dimensional dosimetric comparison of radiation therapy treatment planning of the pancreas.

Authors:  J C Chu; L J Solin; C C Hwang; H Kessler; G E Hanks
Journal:  Med Dosim       Date:  1992       Impact factor: 1.482

View more
  6 in total

1.  Dosimetric impact of gastrointestinal air column in radiation treatment of pancreatic cancer.

Authors:  Neil C Estabrook; Jonathan B Corn; Marvene M Ewing; Higinia R Cardenes; Indra J Das
Journal:  Br J Radiol       Date:  2017-12-22       Impact factor: 3.039

Review 2.  Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?

Authors:  Michael D Chuong; Drexell H Boggs; Kruti N Patel; William F Regine
Journal:  J Gastrointest Oncol       Date:  2014-06

3.  Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer.

Authors:  Michael Chuong; Shahed N Badiyan; Man Yam; Zuofeng Li; Katja Langen; William Regine; Christopher Morris; James Snider; Minesh Mehta; Soon Huh; Michael Rutenberg; Romaine C Nichols
Journal:  J Gastrointest Oncol       Date:  2018-08

4.  Evaluation of initial setup errors of two immobilization devices for lung stereotactic body radiation therapy (SBRT).

Authors:  Yoshihiro Ueda; Teruki Teshima; Higinia Cárdenes; Indra J Das
Journal:  J Appl Clin Med Phys       Date:  2017-05-14       Impact factor: 2.102

5.  Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer.

Authors:  Sarah Stefanowicz; Kristin Stützer; Sebastian Zschaeck; Annika Jakobi; Esther G C Troost
Journal:  Radiat Oncol       Date:  2018-11-22       Impact factor: 3.481

6.  An Investigation of Non-Coplanar Volumetric Modulated Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer Using a Trajectory Optimization Method.

Authors:  Gong Wang; Hao Wang; Hongqing Zhuang; Ruijie Yang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.